Structural biologists at The Hong Kong University of Science and Technology (HKUST) together with researchers at the AIDS Institute, The University of Hong Kong (HKU), Department of Microbiology, School of Clinical Medicine, the LKS Faculty of Medicine of The University of Hong Kong (HKUMed) and the State Key Laboratory of Emerging Infectious Diseases, HKU have demonstrated that ZCB11, a broadly neutralising antibody derived from a local mRNA-vaccinee against the spreading Omicron variants of SARS-CoV-2, displays potent antiviral activities against all variants of concern (VOCs), including the dominantly spreading Omicron BA.1, BA1.1 and BA.2. Read More... 

 

Antibody ZCB11 (right column) protects Syrian golden hamsters against SARS-CoV-2 Delta and Omicron lung infection and injury.  PBS (left column) is a negative control. ZB8 (middle column) is another antibody, protecting against Delta but not Omicron.  Cryo-EM structure analysis demonstrates the binding mode of ZCB11 to Omicron spike trimer.

Antibody ZCB11 (right column) protects Syrian golden hamsters against SARS-CoV-2 Delta and Omicron lung infection and injury. PBS (left column) is a negative control. ZB8 (middle column) is another antibody, protecting against Delta but not Omicron. Cryo-EM structure analysis demonstrates the binding mode of ZCB11 to Omicron spike trimer.
Scientific Breakthroughs & Discoveries